Skip to content
Open access

Graph Neural Networks for Predicting Drug-Target Interactions in Rare Disease

Jul 2026 · International Journal of Artificial Intelligence & Robotics (IJAIR) · Vol 8, pp. 50-63 · 0 citations

TL;DR

The proposed framework provides an accurate, scalable, and interpretable computational solution for rare disease drug discovery, supporting prioritization of drug repurposing candidates and therapeutic target identification in data-scarce biomedical environments, subject to future biological and clinical validation.

Abstract

Rare diseases affect millions of people worldwide, yet the discovery of effective treatments remains hindered by limited biological data, sparse drug–target interaction (DTI) information, and the high cost of experimental validation. Existing computational approaches often struggle to maintain predictive performance under such data-constrained conditions. This study aims to develop a robust Graph Neural Network (GNN)-based framework capable of accurately predicting DTIs for rare diseases by leveraging heterogeneous biomedical knowledge graphs and advanced representation learning techniques. The proposed methodology integrates a self-supervised graph contrastive learning module with a rare-disease-aware edge-reweighting mechanism to improve representation quality and preserve disease-specific biological signals during message passing. An experimental evaluation was conducted using benchmark datasets derived from DrugBank, Orphanet, and UniProt across varying levels of data sparsity. The proposed framework achieved AUROC scores of 0.932, 0.904, and 0.859 and AUPRC scores of 0.871, 0.835, and 0.748 under moderate, high, and extreme sparsity conditions, respectively, consistently outperforming state-of-the-art baseline methods. The results further demonstrate that graph contrastive learning and contextual edge reweighting substantially improve predictive robustness and model generalization. In conclusion, the proposed framework provides an accurate, scalable, and interpretable computational solution for rare disease drug discovery, supporting prioritization of drug repurposing candidates and therapeutic target identification in data-scarce biomedical environments, subject to future biological and clinical validation.

Read PDF

Similar papers

Open access Sep 2026

Heterogeneous Graph Contrastive Learning for Drug-Gene-Disease Motif Prediction

Drug repurposing and target discovery offer critical strategies for advancing therapeutic development by uncovering the potential biological pathways and novel associations among drugs, genes, and diseases. However, experimental discovery remains expensive and time-consuming, which limits the scalability of large-scale...

Hong-Sheng Xie, Yuan Gao, S. Ke et al. · 0 citations
Aug 2026

A Knowledge Graph–Driven Multimodal Framework for Drug–Disease Association Prediction

KGDDA is proposed, a multimodal framework designed for drug-disease association prediction that synergistically integrates KGs with medical ontologies, enabling the adaptive capture of intricate drug-disease interactions.

Qi-Chang Zhao, Qiao Ling, Muhammad Habibulla Alamin et al. · 0 citations
#graph neural networks Open access Sep 2026

Heterogeneous graph neural networks with biological prior knowledge for interpretable drug repurposing in triple-negative breast cancer

Paired Wilcoxon tests in 39 AURORA-US patients with matched primary and metastatic samples confirm that 4 of the 10 IG-identified TFs are significantly altered during metastatic progression after Bonferroni correction.

C. Fernandez-Lozano, David Ferreiro, Patricia V.-del-Río · 0 citations
Open access Oct 2026

A benchmark study comparing deep learning and path analysis approaches for multi-class link prediction on a disease-specific literature knowledge graph.

Identifying and understanding multi-type drug-drug interactions and their associated toxicities is crucial for preventing adverse outcomes, especially in vulnerable populations, such as cancer patients, who may already have compromised health statuses. This paper provides a benchmark study that compares various commonl...

Marios Vottas, Konstantinos Bougiatiotis, Fotis Aisopos et al. · 0 citations
Aug 2026

Predicting circRNA-Drug Sensitivity Using Integrated Hybrid Graph and Molecular Features.

Case studies further validated predicted circRNA-drug associations, including cisplatin, enzalutamide, and sorafenib, against published experimental findings, demonstrating HMCDSP's capacity to reveal clinically relevant biomarkers and inform personalized therapeutic strategies.

Yong-Tian Wang, Wen-Kai Shen, Jiahao Li et al. · 1 citation
Aug 2026

MolADR: Multi-Scale Complementary Learning of Dual-Granularity Molecules and Knowledge Graphs for ADR Prediction in Drug Combinations.

MolADR is proposed, a multiscale complementary learning framework that integrates GNN-based KG learning with dual-granularity molecular cross-attention modeling to combine macro-level biomedical associations with microlevel molecular interaction cues, suggesting its ability to highlight chemically plausible atoms and f...

Yi-Fan Qi, Qing-Wen Ren, Chen-Xu Wang et al. · 0 citations

We use cookies to run the site and, with your consent, for analytics and to show ads. See our Cookie Policy.